RedHill Biopharma (RDHL) Change in Working Capital: 2017-2022
- RedHill Biopharma's Change in Working Capital rose 86.68% to $8.8 million in Q2 2022 from the same period last year, while for Jun 2022 it was $17.4 million, marking a year-over-year increase of 116.00%. This contributed to the annual value of -$2.1 million for FY2024, which is 113.14% down from last year.
- Per RedHill Biopharma's latest filing, its Change in Working Capital stood at $8.8 million for Q2 2022, which was up 86.68% from $4.7 million recorded in Q2 2021.
- In the past 5 years, RedHill Biopharma's Change in Working Capital ranged from a high of $8.8 million in Q2 2022 and a low of -$542,000 during Q2 2018.
- Its 3-year average for Change in Working Capital is $5.6 million, with a median of $4.7 million in 2021.
- Data for RedHill Biopharma's Change in Working Capital shows a peak YoY skyrocketed of 400.00% (in 2020) over the last 5 years.
- Quarterly analysis of 5 years shows RedHill Biopharma's Change in Working Capital stood at -$542,000 in 2018, then spiked by 219.37% to $647,000 in 2019, then surged by 400.00% to $3.2 million in 2020, then skyrocketed by 45.75% to $4.7 million in 2021, then skyrocketed by 86.68% to $8.8 million in 2022.
- Its last three reported values are $8.8 million in Q2 2022, $4.7 million for Q2 2021, and $3.2 million during Q2 2020.
